engleski

TOBREX IN TREATMENT OF CONJUNCTIVITIS

Purpose. Tobramycin (Tobrex) is a broad spectrum antibiotic of the aminoglicoside group. The aim of the study was to evaluate the efficacy and safety of Tobrex in treatment of conjunctivitis. Methods. There were 70 eyes included in this prospective study all with conjunctivitis of presumably bacterial origin. The microbiology swabs were taken from each eye before the treatment was initiated and the 11th day of the drops administration. The intensity of the symptoms (itching, pain, photophobia) and clinical signs (erithema, secretion, hyperemia, tearing and epithelial corneal wounds) was graded on 0-3 scale on the first, fifth and eleventh day after the therapy was started. The average therapy duration was 10 days. The drops were administered 4 times a day and the ointment was given 2 times a day. The efficacy of the therapy was determined by physician&#8217 ; ; s clinical evaluation and the sterility of the microbiology swabs. At the end of the treatment the patients were designated as completely healed, clinically improved, unchanged or worse. Results. Out of 70 eyes that were presumed to have bacterial conjunctivitis 56 had bacteria positive conjunctival swabs. No patients developed Tobrex relates allergy. After 10 days of Tobrex administration 96.4 % of eyes were designated as clinically cured or improved while the control conjunctival swabs were sterile in 85.7% of eyes. Conclusion. Tobramycin (Tobrex) was shown to be effective in symptoms and clinical sign control and in rapid eradication of pathogen bacteria that were responsible for the infection. Therefore tobramycin should be considered as a valid alternative to other antibiotics in treatment of conjunctivitis.

tobramycin; conjunctivitis; treatment

nije evidentirano